Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pardoprunox
- Development stage
- Phase 3
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pardoprunox is an investigational small molecule drug developed primarily for the treatment of Parkinson's disease. It acts as a partial agonist at dopamine D2 and D3 receptors and as a full agonist at serotonin 5-HT1A receptors. Pardoprunox also exhibits lower affinity binding to dopamine D4, alpha-1 adrenergic, alpha-2 adrenergic, and serotonin 5-HT7 receptors. Its pharmacological profile was designed to provide antiparkinsonian effects with potentially fewer dopaminergic side effects such as dyskinesia and psychosis compared to other agents in its class. The drug reached phase III clinical trials for Parkinson's disease but development was discontinued before approval. It was also investigated for depression and anxiety but these indications were not pursued further[1][2][3][4][5].
- Other names
- pardoprunox hydrochloride
02
Targets
DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HTR7 (5-hydroxytryptamine receptor 7)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)ADRA2A (α2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on pardoprunox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pardoprunox.